Anti-cyclic citrullinated peptide antibody in systematic sclerosis

Clinical and Experimental Rheumatology

Volumn 26, Issue 4, 2008, Pages 542-547

  Morita, Yukiko ^a   Muro, Yoshinao ^a   Sigiura, Kazsumitsu ^a   Tomita, Yasushi ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Anti cyclic citrullinated peptide antibody; Overlap syndrome; Rheumatoid arthritis; Systematic sclerosis

Indexed keywords

CYCLIC CITRULLINATED PEPTIDE ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; STROMELYSIN;

ADULT; AGED; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTIBODY TITER; ARTHRALGIA; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; INTERSTITIAL PNEUMONIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SENSITIVITY AND SPECIFICITY; SJOEGREN SYNDROME; SYSTEMIC SCLEROSIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; CASE-CONTROL STUDIES; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; MALE; MIDDLE AGED; PEPTIDES, CYCLIC; RHEUMATOID FACTOR; SCLERODERMA, SYSTEMIC; SYNDROME; YOUNG ADULT;

EID: 52649163944     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. MEDSGER TA: Progressive systemic sclerosis: skeletal muscle involvement. Clin Rheum Dis 1979; 5: 103-13.
2. BLOCKA K: Systemic sclerosis. Philadelphia, Penn: Williams & Wilkins; 1996.
3. SEIBOLD JR: Kelley's textbook of rheumatology, 6th ed. Philadelphia, Penn: WB Saunders; 2001.
4. LA MONTAGNA G, SODANO A, CAPURRO V, MALESCI D, VALENTINI G: The arthropathy of systemic sclerosis: a 12 month prospective clinical and imaging study. Skeletal Radiol 2005; 34: 35-41.
5. HORIKI T, MORIUCHI J, TAKAYA M et al.: The coexistence of systemic sclerosis and rheumatoid arthritis in five patients. Clinical and immunogenetic features suggest a distinct entity. Arthritis Rheum 1996; 39: 152-6.
6. YOSHIHARA Y OBATA K, FUJIMOTO N, YAMASHITA K, HAYAKAWA T, SHIMMEI M: Increased levels of stromelysin-1 and tissue inhibitor of metalloproteinases-1 in sera from patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 969-75.
7. PAREKH R, ISENBERG D, ROOK G, ROITT I, DWEK R, RADEMACHER T: A comparative analysis of disease-associated changes in the galactosylation of serum IgG. J Autoimmun 1989; 2: 101-14.
8. SUMAR N, BODMAN KB, RADEMACHER TW et al.: Analysis of glycosylation changes in IgG using lectins. J Immunol Methods 1990; 131: 127-36.
9. VAN BOEKEL MAM, VOSSENAAR ER, VAN DEN HOOGEN FHJ, VAN VENROOIJ WJ: Autoantibody systems in rheumatoid arthritis: specificity, sensitivity and diagnostic value. Arthritis Res 2002; 4: 87-93.
10. JANSEN AMA, VAN DER HORST-BRUINSAMA IE, VAN SCHAARDENBURG D, VAN DE STADT RJ, DE KONING MHMT, DIJKMANS BAC: Rheumatoid factor and autoantibodies to cyclic citrullinated peptide differentiate rheumatoid arthritis from undifferentiated polyarthritis in patients with early arthritis. J Rheumatol 2002; 29: 2074-76.
11. BAS S, PERNEGER TV, SEITZ M, TIERCY JM, ROUX-LOMBARD P, GUERNE PA: Diagnostic tests for rheumatoid arthritis: comparison of anti-cyclic citrullinated peptide antibodies, anti-keratin antibodies and IgM rheumatoid factors. Rheumatology 2002; 41: 809-14,
12. BIZZARO N, MAZZANTI G, TONUTTI E, VILLALTA D, TOZZOLI R: Diagnostic accuracy of the anti-citrulline antibody assay for rheumatoid arthritis. Clin Chem 2001; 47: 1089-93.
13. SCHELLEKENS GA, DE JONG BAW, VAN DEN HOOGEN FHJ, VAN DE PUTTE LBA, VAN VENROOIJ WJ: Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J Clin Invest 1999; 101: 273-91.
14. MEYER O, LABARRE C, DOUGADOS M et al.: Anticitrullinated protein/ peptide antibody assays in early rheumatoid arthritis for predicting five year radiographic damage. Ann Rheum Dis 2003; 62: 120-6.
15. FORSLIND K, AHLMEN M, EBERHARDT K, HAFSTROM I, SVENSSON B, FOR THE BARFOT STUDY GROUP: Prediction of radiological outcome in early rheumatoid arthritis in clinical practice: role of antibodies to citrullinated peptides (anti-CCP). Ann Rheum Dis 2004; 63: 1090-95.
16. DEL VAL DEL AMO N, IBANEZ BOSCH R, FITO MANTECA C, GUTIERREZ POLO R, LOZA CORTINA E: Anti-cyclic citrullinated peptide antibody in rheumatoid arthritis: relation with disease aggressiveness. Clin Exp Rheumatol 2006; 24: 281-86.
17. VAN GAALEN FA, LINN-RASKER SP, VAN VENROOIJ WJ et al.: Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: a prospective cohort study. Arthritis Rheum 2004; 50: 709-15.
18. MARTINEZ JB, VALERO IS, BAUTISTA AJ, RESTREPO JF et al.: Erosive arthropathy: clinical variance in lupus erythematosus and association with anti-CCP case series and review of the literature. Clin Exp Rheumatol 2007; 25: 47-53.
19. ARNETT FC, EDWORTHY SM, BLOCH DA et al.: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24.
20. SUBCOMMITTEE FOR SCLERODERMA CRITERIA OF THE AMERICAN RHEUMATISM ASSOCIATION DIAGNOSTIC AND THERAPEUTIC CRITERIA COMMITTEE: Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23: 581-90.
21. LEROY EC, BLACK C, FLEISHMAJER R et al.: Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988; 15: 202-5.
22. WATANABE A, KODERA M, SUGIURA K et al.: Anti-DFS70 antibodies in 597 healthy hospital workers. Arthritis Rheum. 2004; 50: 892-900.
23. AILUS K, MELAMIES L, TUOMI T, PALOSUO T, AHO K: Measuring rheumatoid factor in nonrheumatoid subjects: immunoturbidimetric assay, latex slide test, and enzyme-linked immunosorbent assay compared. Clin Chem 1991; 37: 1766-69.
24. ICHIKAWA Y, YAMADA C, HORIKI T et al.: Anti-agalactosyl IgG antibodies and isotype profiles of rheumatoid factors in Sjögren's syndrome and rheumatoid arthritis. Clin Exp Rheumatol 1998; 16: 709-15.
25. ZIMMERMANN C, STEINER G, SKRINER K, HASSFELD W, PETERA P, SMOLEN JS: The concurrence of rheumatoid arthritis and limited systemic sclerosis: clinical and serologic characteristics of an overlap syndrome. Arthritis Rheum 1998; 41: 1938-45.
26. TUFFANELLI DL, WINKELMANN RK: Systemic scleroderma: a clinical study of 727 cases. Arch Dermatol 1961; 84: 359-71.
27. DORAN M, WORDSWORTH P, BRESNIHAN B, FITZQERALD O: A distinct syndrome including features of systemic sclerosis, erosive rheumatoid arthritis, anti-topoisomerase antibody, and rheumatoid factor. J Rheumatol 2001; 28: 921-22.
28. MORITA Y, MURO Y, SUGIURA K, TOMITA Y, TAMAKOSHI K: Results of the health assessment questionnaire for Japanese patients with systemic sclerosis - measuring functional impairment in systemic sclerosis versus other connective tissue diseases. Clin Exp Rheumatol 2007; 25: 367-72.
29. INGEGNOLI F, GALBIATI V, ZENI S et al.: Use of antibodies recognizing cyclic citrullinated peptide in the differential diagnosis of joint involvement in systemic scler-osis. Clin Rheumatol 2007; 26: 510-14.
30. G. SZÜCS, Z. SZEKANECZ, E. ZILAHI et al.: Systemic sclerosis-rheumatoid arthritis overlap syndrome: a unique combination of features suggests a distinct genetic, serological and clinical entity. Rheumatology 2007; 46: 989-93.